OncoMed Announces Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
OncoMed Pharma (OMED) Tops Q2 EPS by 10c
August 2, 2017 4:59 PM EDTOncoMed Pharma (NASDAQ: OMED) reported Q2 EPS of ($0.40), $0.10 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $4.85 million.
For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.
... More